Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03492151 · ClinicalTrials.gov registry record
Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions
A clinical trial of Pancreatic Cyst, sponsored by Ohio State University Comprehensive Cancer Center.
- Recruiting
- Registry status
- 500
- Enrollment target
- 10
- Study locations
NCT03492151: Recruiting study of Pancreatic Cyst, sponsored by Ohio State University Comprehensive Cancer Center.
NCT03492151 is a study of Pancreatic Cyst that is actively recruiting participants, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 500 participants, roughly in line with the 522-participant average among 18 other Pancreatic Cyst trials with a reported enrollment target. The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03492151, a study of Pancreatic Cyst, is actively recruiting participants, sponsored by Ohio State University Comprehensive Cancer Center.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 10
- Study locations
Study Summary
The study schema is shown in Figure 4. (A) All patients referred to one of the participating academic centers for EUS evaluation of the PCL will be enrolled in the protocol if they satisfy inclusion criteria. Patient consent will be obtained during the clinic visit or prior to their EUS. EUS-guided nCLE imaging is first performed (B) followed by EUS-guided FNA and aspiration of cyst fluid. The cyst fluid is analyzed for CEA and cytology. As per institutional standard of care, the cyst fluid is also sent for molecular analysis. The results of the cyst fluid molecular analysis (B) will be utilized for the most likely diagnosis. Based on institutional multidisciplinary tumor board meetings, surgery is performed as indicated (C). Surgical histopathology serves as "gold standard" for diagnosis. It is anticipated that the majority of patients will undergo surgical resection after their EUS.
Primary Outcome
Diagnostic accuracy of confocal laser endomicroscopy and/or cyst fluid molecular markers and/or composite clinical and imaging features for the diagnosis of mucinous PCLs, PCLs with malignant potential, specific PCL types, and mucinous PCLs with advanced neoplasia.
Conditions Studied
Study Locations (10)
New York
- NYU Langone Health - Garden City
- Icahn School of Medicine at Mount Sinai - New York
Arizona
- Mayo Clinic Scottsdale Campus - Scottsdale
California
- Stanford Hospital - Stanford
Connecticut
- Yale School of Medicine - New Haven
Indiana
- Parkview Hospital Randallia - Fort Wayne
Maryland
- The Johns Hopkins Hospital - Baltimore
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Ohio
- The Ohio State University Wexner Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2026-12-31 |
What NCT03492151 shows while recruiting
NCT03492151 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 522-participant average among 18 other Pancreatic Cyst trials with a reported enrollment target.
The record links to 1 condition, with Pancreatic Cyst appearing as the primary indexed condition, and to 0 interventions.
NCT03492151 lists 10 locations in 9 states (New York, Arizona, California).
Frequently Asked Questions
What is clinical trial NCT03492151 about?
NCT03492151 is a clinical study titled "Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions". The study schema is shown in Figure 4. (A) All patients referred to one of the participating academic centers for EUS evaluation of the PCL will be enrolled in the protocol if they satisfy inclusion criteria. Patient consent will be obtained during the clinic visit or prior to their EUS. EUS-guided ...
What is the current status of trial NCT03492151?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2018-10-01. Estimated completion is 2026-12-31.
What conditions does trial NCT03492151 study?
This clinical trial studies the following conditions: Pancreatic Cyst.
Who is sponsoring clinical trial NCT03492151?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03492151 being conducted?
This trial has 10 study locations across Arizona, California, Connecticut, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cyst
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03492151's enrollment target sits among peer trials
500 5th of 18 higher than 13 of 18 other Pancreatic Cyst trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cyst trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms
RECRUITING
-
EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
RECRUITING · NA
-
Evaluation of Pancreatic Cystic Lesions Via EUS-guided Fine Needle Aspiration With and Without Micro Forceps Biopsies
RECRUITING · NA
-
UCSF PANC Cyst Registry
RECRUITING
-
PROMs After Pancreatectomy
RECRUITING
-
Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI